{
    "info": {
        "nct_id": "NCT06751589",
        "official_title": "Pilot Weight Loss Intervention With Dual GIP/GLP-1 Receptor Agonist Therapy in Patients With Endometrial Cancer and Obesity, Overweight, With or Without Diabetes",
        "inclusion_criteria": "* Age ≥ 18 years\n* Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2\n* Obesity (defined as BMI ≥ 30 kg/m2) OR Overweight (defined as BMI ≥ 27 kg/m2) with presence of ≥1 weight related comorbid condition OR a diagnosis of Type 2 Diabetes Mellitus with BMI ≥ 25 kg/m2\n* Type 2 Diabetes Mellitus is defined as known history of Type 2 diabetes, HbA1c ≥ 6.5%, fasting blood glucose ≥126 mg/dL on 2 occasions, or random blood glucose ≥ 200 mg/dL with signs and symptoms of diabetes mellitus (weight loss, fatigue, polyuria, polydipsia, vision changes)\n* Patients with new diagnosis of stage I-III endometrial cancer\n* Completed surgery with TH/BSO with no gross residual disease\n* Recommended to undergo curative intent adjuvant chemotherapy at MSK with carboplatin and paclitaxel with or without intravaginal radiation OR cisplatin and concurrent radiation followed by carboplatin and paclitaxel. Patients may consent prior to and up to 3 weeks after the first cycle of chemotherapy.\n* Patients with the following histologic epithelial cell types are eligible: endometrioid adenocarcinoma, serous adenocarcinoma, carcinosarcoma, undifferentiated carcinoma/de-differentiated, clear cell adenocarcinoma, mixed epithelial carcinoma, adenocarcinoma not otherwise specified (N.O.S.), and mucinous adenocarcinoma.\n* Patient has adequate organ function, as defined by the following laboratory values:\n\n  1. Creatinine clearance (per Cockcroft-Gault formula) ≥30 mL/min\n  2. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤3.0 × ULN.\n  3. Total serum bilirubin ≤ 1.5 × ULN except for patients with Gilbert's syndrome who may be included if the total serum bilirubin is ≤3.0 × ULN or direct bilirubin ≤ 1.5 × ULN.\n* Insurance approval for tirzepatide or semaglutide (alternative) or willingness to pay out-of-pocket for tirzepatide or semaglutide (alternative) for duration of study period\n* Patients must be capable and willing to learn how to self-inject study drug, as required for this protocol (visually impaired persons who are not able to perform the injections must have the assistance of a sighted individual trained to inject study drug; persons with physical limitations who are not able to perform the injections must have the assistance of an individual trained to inject study drug) and administer study drug injection (or receive an injection from a trained individual if visually impaired or with physical limitations)\n* Not pregnant and not nursing\n* English speaking or a family member or caregiver who speaks English and is able to assist with smart phone or tablet based Keenoa app or paper dietary recall handout (if no access to smart phone or tablet).\nHealthy volunteers allowed\nMust be FEMALE\nMust have minimum age of 18 Years",
        "exclusion_criteria": "* Known Type 1 diabetes\n* Known GAD, Islet Cell, or Zn Transporter 8 antibodies\n* History of gastroparesis\n* High risk for aspiration\n* Active or history of chronic or acute pancreatitis\n* History of elevated calcitonin\n* Personal or family history of Medullary Thyroid Carcinoma with Multiple Endocrine Neoplasia-2 syndrome\n* Patients with a prior surgical, endoscopic, and/or device-based therapy (for example, mucosal ablation, gastric artery embolization, intragastric balloon and duodenojejunal bypass sleeve) for obesity within the past two years\n* Patients with removal of device-based therapy for obesity within the last 6 months\n* Current GIP/GLP-1 or GLP-1 receptor agonist use or prior intolerance of GIP/GLP-1 or GLP-1 receptor agonist\n* Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial.\n* Known intolerance to study drug(s) or any of the excipients.",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "Must be FEMALE",
            "criterions": [
                {
                    "exact_snippets": "Must be FEMALE",
                    "criterion": "sex",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": "female"
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Creatinine clearance (per Cockcroft-Gault formula) ≥30 mL/min",
            "criterions": [
                {
                    "exact_snippets": "Creatinine clearance (per Cockcroft-Gault formula) ≥30 mL/min",
                    "criterion": "creatinine clearance",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 30,
                                "unit": "mL/min"
                            }
                        },
                        {
                            "requirement_type": "calculation method",
                            "expected_value": "Cockcroft-Gault formula"
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Age ≥ 18 years",
            "criterions": [
                {
                    "exact_snippets": "Age ≥ 18 years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Completed surgery with TH/BSO with no gross residual disease",
            "criterions": [
                {
                    "exact_snippets": "Completed surgery with TH/BSO",
                    "criterion": "surgery type",
                    "requirements": [
                        {
                            "requirement_type": "type",
                            "expected_value": [
                                "TH",
                                "BSO"
                            ]
                        },
                        {
                            "requirement_type": "completion_status",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "no gross residual disease",
                    "criterion": "gross residual disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patient has adequate organ function, as defined by the following laboratory values:",
            "criterions": [
                {
                    "exact_snippets": "adequate organ function",
                    "criterion": "organ function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2",
            "criterions": [
                {
                    "exact_snippets": "Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2",
                    "criterion": "ECOG performance status",
                    "requirements": [
                        {
                            "requirement_type": "score",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "N/A"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients with the following histologic epithelial cell types are eligible: endometrioid adenocarcinoma, serous adenocarcinoma, carcinosarcoma, undifferentiated carcinoma/de-differentiated, clear cell adenocarcinoma, mixed epithelial carcinoma, adenocarcinoma not otherwise specified (N.O.S.), and mucinous adenocarcinoma.",
            "criterions": [
                {
                    "exact_snippets": "histologic epithelial cell types ... endometrioid adenocarcinoma, serous adenocarcinoma, carcinosarcoma, undifferentiated carcinoma/de-differentiated, clear cell adenocarcinoma, mixed epithelial carcinoma, adenocarcinoma not otherwise specified (N.O.S.), and mucinous adenocarcinoma",
                    "criterion": "histologic epithelial cell type",
                    "requirements": [
                        {
                            "requirement_type": "allowed_types",
                            "expected_value": [
                                "endometrioid adenocarcinoma",
                                "serous adenocarcinoma",
                                "carcinosarcoma",
                                "undifferentiated carcinoma",
                                "de-differentiated carcinoma",
                                "clear cell adenocarcinoma",
                                "mixed epithelial carcinoma",
                                "adenocarcinoma not otherwise specified (N.O.S.)",
                                "mucinous adenocarcinoma"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients with new diagnosis of stage I-III endometrial cancer",
            "criterions": [
                {
                    "exact_snippets": "new diagnosis of stage I-III endometrial cancer",
                    "criterion": "endometrial cancer",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis_status",
                            "expected_value": "new diagnosis"
                        },
                        {
                            "requirement_type": "stage",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 1,
                                        "unit": "stage"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 3,
                                        "unit": "stage"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Type 2 Diabetes Mellitus is defined as known history of Type 2 diabetes, HbA1c ≥ 6.5%, fasting blood glucose ≥126 mg/dL on 2 occasions, or random blood glucose ≥ 200 mg/dL with signs and symptoms of diabetes mellitus (weight loss, fatigue, polyuria, polydipsia, vision changes)",
            "criterions": [
                {
                    "exact_snippets": "known history of Type 2 diabetes",
                    "criterion": "Type 2 diabetes mellitus",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "HbA1c ≥ 6.5%",
                    "criterion": "HbA1c",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": ">=",
                                "value": 6.5,
                                "unit": "%"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "fasting blood glucose ≥126 mg/dL on 2 occasions",
                    "criterion": "fasting blood glucose",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": ">=",
                                "value": 126,
                                "unit": "mg/dL"
                            }
                        },
                        {
                            "requirement_type": "number of occasions",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "occasions"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "random blood glucose ≥ 200 mg/dL with signs and symptoms of diabetes mellitus (weight loss, fatigue, polyuria, polydipsia, vision changes)",
                    "criterion": "random blood glucose",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": ">=",
                                "value": 200,
                                "unit": "mg/dL"
                            }
                        },
                        {
                            "requirement_type": "signs and symptoms of diabetes mellitus",
                            "expected_value": [
                                "weight loss",
                                "fatigue",
                                "polyuria",
                                "polydipsia",
                                "vision changes"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* English speaking or a family member or caregiver who speaks English and is able to assist with smart phone or tablet based Keenoa app or paper dietary recall handout (if no access to smart phone or tablet).",
            "criterions": [
                {
                    "exact_snippets": "English speaking",
                    "criterion": "English language proficiency",
                    "requirements": [
                        {
                            "requirement_type": "proficiency",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "a family member or caregiver who speaks English and is able to assist with smart phone or tablet based Keenoa app or paper dietary recall handout (if no access to smart phone or tablet)",
                    "criterion": "family member or caregiver English language proficiency and assistance",
                    "requirements": [
                        {
                            "requirement_type": "proficiency",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "assistance with Keenoa app or paper dietary recall handout",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Recommended to undergo curative intent adjuvant chemotherapy at MSK with carboplatin and paclitaxel with or without intravaginal radiation OR cisplatin and concurrent radiation followed by carboplatin and paclitaxel. Patients may consent prior to and up to 3 weeks after the first cycle of chemotherapy.",
            "criterions": [
                {
                    "exact_snippets": "Recommended to undergo curative intent adjuvant chemotherapy at MSK",
                    "criterion": "recommendation for curative intent adjuvant chemotherapy at MSK",
                    "requirements": [
                        {
                            "requirement_type": "recommendation_status",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "with carboplatin and paclitaxel with or without intravaginal radiation OR cisplatin and concurrent radiation followed by carboplatin and paclitaxel",
                    "criterion": "planned chemotherapy and/or radiation regimen",
                    "requirements": [
                        {
                            "requirement_type": "regimen",
                            "expected_value": [
                                "carboplatin and paclitaxel with or without intravaginal radiation",
                                "cisplatin and concurrent radiation followed by carboplatin and paclitaxel"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "Patients may consent prior to and up to 3 weeks after the first cycle of chemotherapy",
                    "criterion": "time from first cycle of chemotherapy to consent",
                    "requirements": [
                        {
                            "requirement_type": "time_window",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": -9999,
                                        "unit": "weeks"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 3,
                                        "unit": "weeks"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Insurance approval for tirzepatide or semaglutide (alternative) or willingness to pay out-of-pocket for tirzepatide or semaglutide (alternative) for duration of study period",
            "criterions": [
                {
                    "exact_snippets": "Insurance approval for tirzepatide or semaglutide (alternative)",
                    "criterion": "insurance approval for tirzepatide or semaglutide",
                    "requirements": [
                        {
                            "requirement_type": "approval_status",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "willingness to pay out-of-pocket for tirzepatide or semaglutide (alternative) for duration of study period",
                    "criterion": "willingness to pay out-of-pocket for tirzepatide or semaglutide",
                    "requirements": [
                        {
                            "requirement_type": "willingness",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "duration",
                            "expected_value": "for duration of study period"
                        }
                    ]
                }
            ]
        },
        {
            "line": "3. Total serum bilirubin ≤ 1.5 × ULN except for patients with Gilbert's syndrome who may be included if the total serum bilirubin is ≤3.0 × ULN or direct bilirubin ≤ 1.5 × ULN.",
            "criterions": [
                {
                    "exact_snippets": "Total serum bilirubin ≤ 1.5 × ULN",
                    "criterion": "total serum bilirubin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "patients with Gilbert's syndrome ... total serum bilirubin is ≤3.0 × ULN",
                    "criterion": "total serum bilirubin (in patients with Gilbert's syndrome)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3.0,
                                "unit": "ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "patients with Gilbert's syndrome ... direct bilirubin ≤ 1.5 × ULN",
                    "criterion": "direct bilirubin (in patients with Gilbert's syndrome)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "ULN"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤3.0 × ULN.",
            "criterions": [
                {
                    "exact_snippets": "Alanine aminotransferase (ALT) ... ≤3.0 × ULN",
                    "criterion": "alanine aminotransferase (ALT) level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3.0,
                                "unit": "ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "aspartate aminotransferase (AST) ≤3.0 × ULN",
                    "criterion": "aspartate aminotransferase (AST) level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3.0,
                                "unit": "ULN"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Obesity (defined as BMI ≥ 30 kg/m2) OR Overweight (defined as BMI ≥ 27 kg/m2) with presence of ≥1 weight related comorbid condition OR a diagnosis of Type 2 Diabetes Mellitus with BMI ≥ 25 kg/m2",
            "criterions": [
                {
                    "exact_snippets": "Obesity (defined as BMI ≥ 30 kg/m2)",
                    "criterion": "obesity",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "BMI",
                            "expected_value": {
                                "operator": ">=",
                                "value": 30,
                                "unit": "kg/m2"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Overweight (defined as BMI ≥ 27 kg/m2) with presence of ≥1 weight related comorbid condition",
                    "criterion": "overweight with weight related comorbid condition",
                    "requirements": [
                        {
                            "requirement_type": "BMI",
                            "expected_value": {
                                "operator": ">=",
                                "value": 27,
                                "unit": "kg/m2"
                            }
                        },
                        {
                            "requirement_type": "weight related comorbid condition count",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": ""
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "diagnosis of Type 2 Diabetes Mellitus with BMI ≥ 25 kg/m2",
                    "criterion": "Type 2 Diabetes Mellitus with BMI",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis",
                            "expected_value": "Type 2 Diabetes Mellitus"
                        },
                        {
                            "requirement_type": "BMI",
                            "expected_value": {
                                "operator": ">=",
                                "value": 25,
                                "unit": "kg/m2"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients must be capable and willing to learn how to self-inject study drug, as required for this protocol (visually impaired persons who are not able to perform the injections must have the assistance of a sighted individual trained to inject study drug; persons with physical limitations who are not able to perform the injections must have the assistance of an individual trained to inject study drug) and administer study drug injection (or receive an injection from a trained individual if visually impaired or with physical limitations)",
            "criterions": [
                {
                    "exact_snippets": "Patients must be capable and willing to learn how to self-inject study drug",
                    "criterion": "ability to learn self-injection of study drug",
                    "requirements": [
                        {
                            "requirement_type": "capability",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "willingness",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "visually impaired persons who are not able to perform the injections must have the assistance of a sighted individual trained to inject study drug",
                    "criterion": "visual impairment and ability to self-inject",
                    "requirements": [
                        {
                            "requirement_type": "visual impairment",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "ability to self-inject",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "assistance by sighted trained individual",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "persons with physical limitations who are not able to perform the injections must have the assistance of an individual trained to inject study drug",
                    "criterion": "physical limitations and ability to self-inject",
                    "requirements": [
                        {
                            "requirement_type": "physical limitations",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "ability to self-inject",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "assistance by trained individual",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "administer study drug injection (or receive an injection from a trained individual if visually impaired or with physical limitations)",
                    "criterion": "administration of study drug injection",
                    "requirements": [
                        {
                            "requirement_type": "administration method",
                            "expected_value": [
                                "self-administered",
                                "administered by trained individual if visually impaired or with physical limitations"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Not pregnant and not nursing",
            "criterions": [
                {
                    "exact_snippets": "Not pregnant",
                    "criterion": "pregnancy status",
                    "requirements": [
                        {
                            "requirement_type": "pregnant",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "not nursing",
                    "criterion": "nursing status",
                    "requirements": [
                        {
                            "requirement_type": "nursing",
                            "expected_value": false
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "* Patients with a prior surgical, endoscopic, and/or device-based therapy (for example, mucosal ablation, gastric artery embolization, intragastric balloon and duodenojejunal bypass sleeve) for obesity within the past two years",
            "criterions": [
                {
                    "exact_snippets": "prior surgical, endoscopic, and/or device-based therapy (for example, mucosal ablation, gastric artery embolization, intragastric balloon and duodenojejunal bypass sleeve) for obesity within the past two years",
                    "criterion": "prior therapy for obesity",
                    "requirements": [
                        {
                            "requirement_type": "type",
                            "expected_value": [
                                "surgical",
                                "endoscopic",
                                "device-based"
                            ]
                        },
                        {
                            "requirement_type": "examples",
                            "expected_value": [
                                "mucosal ablation",
                                "gastric artery embolization",
                                "intragastric balloon",
                                "duodenojejunal bypass sleeve"
                            ]
                        },
                        {
                            "requirement_type": "timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of elevated calcitonin",
            "criterions": [
                {
                    "exact_snippets": "History of elevated calcitonin",
                    "criterion": "calcitonin level",
                    "requirements": [
                        {
                            "requirement_type": "history of elevation",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of gastroparesis",
            "criterions": [
                {
                    "exact_snippets": "History of gastroparesis",
                    "criterion": "gastroparesis",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Known intolerance to study drug(s) or any of the excipients.",
            "criterions": [
                {
                    "exact_snippets": "Known intolerance to study drug(s)",
                    "criterion": "intolerance to study drug(s)",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Known intolerance to ... any of the excipients",
                    "criterion": "intolerance to excipients",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Personal or family history of Medullary Thyroid Carcinoma with Multiple Endocrine Neoplasia-2 syndrome",
            "criterions": [
                {
                    "exact_snippets": "Personal ... history of Medullary Thyroid Carcinoma",
                    "criterion": "personal history of Medullary Thyroid Carcinoma",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "family history of Medullary Thyroid Carcinoma",
                    "criterion": "family history of Medullary Thyroid Carcinoma",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Multiple Endocrine Neoplasia-2 syndrome",
                    "criterion": "Multiple Endocrine Neoplasia-2 syndrome",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Known GAD, Islet Cell, or Zn Transporter 8 antibodies",
            "criterions": [
                {
                    "exact_snippets": "Known GAD ... antibodies",
                    "criterion": "GAD antibodies",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Islet Cell ... antibodies",
                    "criterion": "Islet Cell antibodies",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Zn Transporter 8 antibodies",
                    "criterion": "Zn Transporter 8 antibodies",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* High risk for aspiration",
            "criterions": [
                {
                    "exact_snippets": "High risk for aspiration",
                    "criterion": "risk for aspiration",
                    "requirements": [
                        {
                            "requirement_type": "risk level",
                            "expected_value": "high"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Active or history of chronic or acute pancreatitis",
            "criterions": [
                {
                    "exact_snippets": "Active or history of chronic or acute pancreatitis",
                    "criterion": "pancreatitis",
                    "requirements": [
                        {
                            "requirement_type": "presence or history",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "type",
                            "expected_value": [
                                "chronic",
                                "acute"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Current GIP/GLP-1 or GLP-1 receptor agonist use or prior intolerance of GIP/GLP-1 or GLP-1 receptor agonist",
            "criterions": [
                {
                    "exact_snippets": "Current GIP/GLP-1 or GLP-1 receptor agonist use",
                    "criterion": "GIP/GLP-1 or GLP-1 receptor agonist use",
                    "requirements": [
                        {
                            "requirement_type": "current use",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "prior intolerance of GIP/GLP-1 or GLP-1 receptor agonist",
                    "criterion": "GIP/GLP-1 or GLP-1 receptor agonist intolerance",
                    "requirements": [
                        {
                            "requirement_type": "history of intolerance",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients with removal of device-based therapy for obesity within the last 6 months",
            "criterions": [
                {
                    "exact_snippets": "removal of device-based therapy for obesity",
                    "criterion": "removal of device-based therapy for obesity",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "within the last 6 months",
                    "criterion": "removal of device-based therapy for obesity",
                    "requirements": [
                        {
                            "requirement_type": "time since removal",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial.",
            "criterions": [
                {
                    "exact_snippets": "Patients with a prior or concurrent malignancy",
                    "criterion": "malignancy",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": [
                                "prior",
                                "concurrent"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen",
                    "criterion": "potential to interfere with safety or efficacy assessment of investigational regimen",
                    "requirements": [
                        {
                            "requirement_type": "potential to interfere",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Known Type 1 diabetes",
            "criterions": [
                {
                    "exact_snippets": "Known Type 1 diabetes",
                    "criterion": "Type 1 diabetes",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "awareness/status",
                            "expected_value": "known"
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [],
    "failed_exclusion": [],
    "failed_miscellaneous": []
}